论文部分内容阅读
目的:探讨美洛西林和哌拉西林钠他唑巴坦钠在急诊留观社区获得性肺炎中的应用效果。方法:抽选急诊留观的社区获得性肺炎患者85例并随机数字表法分为两组,观察组(42例)均给予哌拉西林钠他唑巴坦钠治疗,对照组(43例)则给予美洛西林治疗,对比两组患者治疗效果及不良反应发生率差异。结果:观察组患者治疗有效率95.2%,对照组患者治疗有效率79.1%,对比差异显著(P<0.05)。观察组患者不良反应发生率9.5%;对照组患者不良反应发生率9.3%,对比无显著性差异(P>0.05)。结论:哌拉西林钠他唑巴坦钠治疗急诊留观社区获得性肺炎患者相较于美洛西林效果更好,不良反应发生率也未增加,值得临床推广。
Objective: To investigate the clinical effect of mezlocillin and piperacillin-tazobactam on emergency patients with community-acquired pneumonia. Methods: Eighty-five patients with community-acquired pneumonia who were admitted to the emergency department were randomly divided into two groups. The observation group (n = 42) was treated with piperacillin and tazobactam sodium. The control group (n = 43) Then given mezlocillin treatment, compared the two groups of patients treated with adverse reactions and the incidence of differences. Results: The effective rate of treatment group was 95.2% in observation group and 79.1% in control group, the difference was significant (P <0.05). The incidence of adverse reactions in the observation group was 9.5%. The incidence of adverse reactions in the control group was 9.3%, with no significant difference (P> 0.05). Conclusion: Piperacillin and tazobactam sodium are more effective than mezlocillin in the treatment of patients with community-acquired pneumonia in emergency treatment, and the incidence of adverse reactions is not increased, which is worthy of clinical promotion.